IDEAYA BIOSCIENCES INC (IDYA) Stock Price & Overview
NASDAQ:IDYA • US45166A1025
Current stock price
The current stock price of IDYA is 32.74 USD. Today IDYA is up by 0.8%. In the past month the price decreased by -0.88%. In the past year, price increased by 122.57%.
IDYA Key Statistics
- Market Cap
- 2.875B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.31
- Dividend Yield
- N/A
IDYA Stock Performance
IDYA Stock Chart
IDYA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IDYA. When comparing the yearly performance of all stocks, IDYA is one of the better performing stocks in the market, outperforming 91.1% of all stocks.
IDYA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IDYA. No worries on liquidiy or solvency for IDYA as it has an excellent financial health rating, but there are worries on the profitability.
IDYA Earnings
On February 17, 2026 IDYA reported an EPS of -0.94 and a revenue of 10.88M. The company beat EPS expectations (4.76% surprise) and beat revenue expectations (70.85% surprise).
IDYA Forecast & Estimates
25 analysts have analysed IDYA and the average price target is 49.98 USD. This implies a price increase of 52.66% is expected in the next year compared to the current price of 32.74.
For the next year, analysts expect an EPS growth of -203.57% and a revenue growth -79.2% for IDYA
IDYA Groups
Sector & Classification
IDYA Financial Highlights
Over the last trailing twelve months IDYA reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 60.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.21% | ||
| ROE | -11.07% | ||
| Debt/Equity | 0 |
IDYA Ownership
IDYA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IDYA
Company Profile
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 145 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Company Info
IPO: 2019-05-23
IDEAYA BIOSCIENCES INC
7000 Shoreline Ct, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Yujiro Hata
Employees: 145
Phone: 16504436209
IDEAYA BIOSCIENCES INC / IDYA FAQ
What does IDYA do?
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 145 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Can you provide the latest stock price for IDEAYA BIOSCIENCES INC?
The current stock price of IDYA is 32.74 USD. The price increased by 0.8% in the last trading session.
Does IDYA stock pay dividends?
IDYA does not pay a dividend.
What is the ChartMill rating of IDEAYA BIOSCIENCES INC stock?
IDYA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is IDYA stock listed?
IDYA stock is listed on the Nasdaq exchange.
What is the expected growth for IDYA stock?
The Revenue of IDEAYA BIOSCIENCES INC (IDYA) is expected to decline by -79.2% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for IDEAYA BIOSCIENCES INC?
IDEAYA BIOSCIENCES INC (IDYA) has a market capitalization of 2.87B USD. This makes IDYA a Mid Cap stock.